Valo Health Appoints Rita Kale as Chief Financial Officer

Lex­ing­ton, MA – Decem­ber 2, 2025 —Valo Health, Inc. (“Valo”), a com­pa­ny pio­neer­ing the use of human data and AI to accel­er­ate drug dis­cov­ery and devel­op­ment, today announced the appoint­ment of Rita Kale as Chief Finan­cial Offi­cer (CFO). Rita brings more than two decades of glob­al finance lead­er­ship in bio­phar­ma, diag­nos­tics, and tech­nol­o­gy-enabled healthcare.

“We are proud to wel­come Rita Kale as Valo’s Chief Finan­cial Offi­cer dur­ing such a piv­otal time at Valo,” said Bri­an Alexan­der, MD, MPH, CEO of Valo Health. ​“Rita’s deep finan­cial exper­tise and proven track record of strate­gi­cal­ly scal­ing orga­ni­za­tions make her an invalu­able addi­tion to our lead­er­ship team. Her abil­i­ty to align finan­cial strat­e­gy with sci­en­tif­ic inno­va­tion will be instru­men­tal as we accel­er­ate our mis­sion to trans­form drug dis­cov­ery and deliv­er mean­ing­ful impact to patients in the future.”

Rita pre­vi­ous­ly served as CFO and Head of Cor­po­rate Man­age­ment at Foun­da­tion Med­i­cine, where she played a key role in dri­ving prod­uct expan­sion and oper­a­tional improve­ment. Ear­li­er in her career, she held senior finance lead­er­ship roles at the Roche Group across Asia-Pacif­ic and Sub-Saha­ran Africa; served as coun­try CFO in South Africa and India; and led finance for Glob­al Prod­uct Strat­e­gy in Switzer­land. In these posi­tions, Rita led strate­gic cap­i­tal allo­ca­tion and drove major busi­ness ini­tia­tives across com­plex health­care mar­kets, suc­cess­ful­ly secur­ing fund­ing for mul­ti­ple prod­uct launch­es while accel­er­at­ing orga­ni­za­tion­al growth and scal­ing oper­a­tions. Rita also serves on the board of CareMetx, a lead­ing patient access ser­vices company.

“I’m thrilled to join Valo at such a trans­for­ma­tive time for the com­pa­ny,” said Rita Kale. ​“Valo’s vision, plat­form, and team are out­stand­ing. I look for­ward to com­bin­ing cor­po­rate strat­e­gy and oper­a­tional exe­cu­tion to help accel­er­ate our mission.”

Valo is trans­form­ing drug dis­cov­ery through AI-enabled human causal biol­o­gy and pre­dic­tive chem­istry. The com­pa­ny advances its own pipeline of ther­a­peu­tic can­di­dates, and part­ners with phar­ma­ceu­ti­cal com­pa­nies to accel­er­ate their pre-clin­i­cal R&D. By inte­grat­ing Valo’s ear­ly R&D capa­bil­i­ties with the clin­i­cal devel­op­ment exper­tise and scale of its phar­ma­ceu­ti­cal part­ners through a frac­tion­al port­fo­lio mod­el, Valo aims to deliv­er more trans­for­ma­tive med­i­cines to patients faster.

About Valo Health:
Valo is redefin­ing drug dis­cov­ery and devel­op­ment through its AI-enabled human causal biol­o­gy and closed loop chem­istry plat­forms. Valo uses AI to under­stand dis­ease causal­i­ty, iden­ti­fy patient sub­types across het­ero­ge­neous dis­eases, and pin­point nov­el drug tar­gets. The com­pa­ny val­i­dates tar­gets using pro­pri­etary 3D engi­neered human tis­sue mod­els that mim­ic mature human phys­i­ol­o­gy and struc­ture. The Company’s closed loop chem­istry plat­form enables rapid devel­op­ment of poten­tial mol­e­cules from tril­lions of start­ing points. Valo’s approach aims to iden­ti­fy more impact­ful drug tar­gets and small mol­e­cule ther­a­peu­tics, faster, and with greater pre­ci­sion than tra­di­tion­al R&D meth­ods. Valo was found­ed by Flag­ship Pio­neer­ing in 2019. Fol­low us on LinkedIn and X.

Media Con­tact:
Erin Smith
esmith@​valohealth.​com